

DOI: 10.4274/jcrpe.galenos.2020.2020.0067

Care report

A Case of Familial Male-Limited Precocious Puberty with a Novel Mutation

Short title: Novel Mutation Causing FMPP

Shilpa Gurnurkar^{1,2}, Emily DiLillo¹, Mauri Carakushansky^{1,2}

¹Department of Pediatrics, ²Department of Pediatrics, Division of Pediatric Endocrinology, Nemours Children's Hospital, Orlando, Florida

What is already known on this topic?

Familial Male-Limited Precocious Puberty (FMPP) is a very rare cause of precocious puberty seen exclusively in males which results in early onset puberty, rapid skeletal maturation and compromised final adult height if not treated. Very limited data is available regarding treatment and there are no consensus guidelines.

What this study adds?

We report a novel mutation in the LHCGR causing FMPP in a very young child who presented with puberty at 6 months of age and is being successfully treated. Our report adds to the very scarce information available about this condition.

Abstract

Familial Male-Limited Precocious Puberty (FMPP), also known as testotoxicosis, is a rare cause of precocious puberty in males. It is caused by a mutation in the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) gene, resulting in the receptor to be constitutively activated. This causes excessive production of testosterone, leading to precocious puberty in males. Generally, boys present with signs of puberty, such as pubic hair growth, acne, and increased height velocity around the age of 2-4 years old. Like any other cause of precocious puberty, the goal of treatment is to prevent virilization and also delay closure of the epiphyseal plates to maintain adult height potential. Treatment therefore is aimed at decreasing the effects of testosterone, as well as stop the conversion of testosterone to estrogen. Because the disorder is so rare, little is known about the long-term effects of treatment; however, studies using bicalutamide and anastrozole have been promising. In this report, we present a case of FMPP with a novel mutation in the LHCGR gene, who has been responding well to therapy using both drugs.

Keywords: Familial male limited precocious puberty, bone age, short stature, adult height

Shilpa Gurnurkar, Department of Pediatrics, ²Department of Pediatrics, Division of Pediatric Endocrinology, Nemours Children's Hospital, Orlando, Florida

+407-558-1161

shilpa.gurnurkar@nemours.org

Submitted: 02-Apr-2020

Accept: 07-Jul-2020

<https://orcid.org/0000-0002-8572-5160>

Introduction

The luteinizing hormone/chorionic gonadotropin receptor (LHCGR), a G-protein coupled receptor, is present on multiple cell types including ovarian theca cells, granulosa cells, and testicular Leydig cells (1). Under normal conditions, it is activated by Luteinizing hormone (LH) and Human chorionic gonadotropin (HCG). It is important for normal sexual development and production of sex steroids (1). The gene for the LHCGR is located on chromosome 2p21, and is the genetic basis of Familial Male-Limited Precocious Puberty (FMPP), also known as testotoxicosis.

An activating mutation in the LHCGR may occur de novo or may be inherited in an autosomal dominant manner. The commonly reported genetic mutation is due to a substitution of an A to a G, which causes a change from aspartate to glycine, in the 578 position of the LHCGR (2). This small change causes the protein to be constitutively activated without any input from LH, leading to excessive sex hormone production.

Interestingly, activating LHCGR mutations only affect phenotype in males. There are two proposed theories as to why females are not affected: LH and follicle stimulating hormone (FSH) are both required to stimulate hormone synthesis, and that the activation of LH receptor (LHR) alone would not cause symptoms (2). Additionally, it is proposed that the degree of dysfunction is simply not high enough to cause symptoms (3). Regardless, the excessive production of testosterone causes early signs of puberty such as pubic hair growth, increased penile length and acne from direct effects of testosterone and dihydrotestosterone on the testosterone receptor; as well as increased height velocity with significant bone age advancement from conversion of androgens to estrogen by the enzyme aromatase. Generally, boys present around the age of 2-4 years old. Without treatment, rapid skeletal maturation occurs with a negative impact on final adult height.

Treatment goals are twofold: to decrease the effects of testosterone, typically through the use of anti-androgen agents; as well as to inhibit the conversion of testosterone to estrogen through the use of aromatase inhibitors. Multiple different medications have

been trialed, but most recent studies show promising results using bicalutamide (an anti-androgen agent), and anastrozole (a third-generation aromatase inhibitor) (4, 5, 6, 7, 8). Because the disorder is so rare, little is known about the long-term effects of treatment; however, studies using of bicalutamide and anastrozole have shown improved height potential (5, 6). In one study, final adult height was only 0.4 standard deviations below that of the general US male population (6).

Here, we present a case of FMPP with a novel mutation in the LHCGR gene, who has been responding well to bicalutamide and anastrozole therapy with marked decrease in growth velocity, pubertal progression and skeletal advancement.

Case

A 16-month-old male presented to our pediatric endocrinology clinic due to concerns of precocious puberty. His parents noticed presence of pubic hair at 6 months of age. Parents also noted a rapid growth acceleration. Parents denied exposure to creams, gels, or medications containing testosterone and there was no known history of early puberty or short stature in the family. Upon presentation, his height was over the 99th percentile while his target height was at the 50th percentile. Physical examination revealed prepubertal testes with pubic hair at Tanner stage II. A bone age was obtained by his pediatrician that was reported as 12-18 months at a chronologic age of 12 months.

Initial lab evaluation revealed normal serum levels of 17 OHP, androstenedione and DHEA-S with a slightly elevated serum LH level (0.7mIU/ml), and a significantly elevated serum testosterone level (289ng/dl). A leuprolide stimulation test was performed that ruled out central precocious puberty and an ACTH stimulation test was also performed that ruled out congenital adrenal hyperplasia. His baseline serum testosterone during the test was 550ng/dl. An MRI of the abdomen and pelvis was reported to be normal. Scrotal ultrasound was obtained that revealed pre-pubertal testes with no testicular masses but testicular microliths were noted bilaterally. An alpha fetoprotein (AFP) level was initially elevated, but repeat was normal, and serum Beta hCG level was normal. Serum IGF-1 and thyroid function were also normal. Rapid skeletal maturation was noted with his bone age advancing to 6 years at a chronological age of 21 months and to 8 years by 26 months of age. At 26 months of age, his stretched penile length was 11cm. At this time, the likely differential diagnoses were FMPP and McCune-Albright syndrome. LH receptor testing was therefore obtained, which revealed a novel heterozygous missense mutation in the LHCGR gene (c.1733A>C; p.Asp.578Ala). The mutation was reported to be a variant of unknown significance though likely in the pathological end of the spectrum by variant analysis with SIFT and PolyPhen.

Based on the patient's classic presentation along with the genetic testing results, he was diagnosed to have FMPP and started on treatment with anastrozole 1 mg daily and bicalutamide 25 mg daily at 2 years and 9 months of age. There was some parental hesitation to start treatment, which delayed it by a few months.

The patient has been tolerating treatment well for approximately over 2 years now with a significant improvement in his linear growth, skeletal maturation and final height prediction (see figure 1). The bone age to chronological age ratio has decreased from 4.5 just at treatment initiation to 3.2, 2 years after treatment. His predicted adult height as has improved from significantly below the 3rd percentile to **162.5cm** which is at the 3rd percentile. Annual scrotal ultrasound testing has revealed stable testicular microliths. Testes have remained prepubertal on exam with prepubertal early morning serum LH levels and prepubertal response to annual leuprolide stimulation testing. After approximately 14 months of treatment, he developed minimal gynecomastia bilaterally, which is a known side effect of androgen receptor antagonists.

Discussion

FMPP is a rare cause of peripheral precocious puberty, exclusively affecting males. Affected males present with early onset of puberty, typically by the age of three, along with accelerated skeletal maturation resulting in premature epiphyseal fusion and compromised final adult height. The overall goal of treatment of FMPP is the same as for any cause of precocious puberty: to minimize virilization and maximize adult height potential.

In the short term, treatment efficacy is monitored using two criteria: physical examination to assess clinical progression and bone ages to assess skeletal maturation and growth potential. The rarity and differences in phenotype of the condition make it difficult to do widespread clinical trials. Treatment has, however evolved over the years, but there is still no consensus on the best treatment.

Before it was known that FMPP was due to an activating mutation of the LHCG receptor, GnRH agonists were the primary treatment. Once the pathophysiology was better understood, anti-androgen medications such as Medroxyprogesterone acetate and cyproterone initially and ketoconazole later became the mainstay for treatment. The former two medications failed to show an improvement in height potential and the latter was associated with serious side effects such as hepatotoxicity and adrenal suppression (9).

It was during this time that adding aromatase inhibitors were trialed in order to prevent early growth plate closure (8, 10, 11). Spironolactone (a weak antiandrogen) and testolactone (an aromatase inhibitor) were trialed with moderate success, and resulted in improvements in skeletal maturation, acne, aggressive behavior, and spontaneous erections (10, 11). However, in one study all boys ended up with secondary central precocious puberty (10). The development of central precocious puberty was likely due to continued elevated poor androgen receptor blockade (6, 12, 13). The fact that patients needed to discontinue spironolactone during GI illnesses, and the fact that it requires multiple daily doses, likely lead to poor compliance. All patients then required addition of deslorelin (a GnRH agonist) (10). Since that trial, more specific and potent medications have become available. Most recent studies have shown good outcomes with anti-androgens such as bicalutamide and third generation aromatase inhibitors such as anastrozole (4, 6, 7, 8). These treatments in conjunction with one another have shown better adult height potential preservation than either alone (5). In one study, antiandrogens alone did not prevent early growth plate closure (5), and in another, anastrozole was ineffective in treating continued aggressiveness (7). Bicalutamide and anastrozole offer the additional advantage of a prolonged half-life that allows for convenient once-daily dosing while other antiandrogen agents would require multiple daily doses.

The data is somewhat variable in regards to long-term outcomes, but results are promising. Adult height is improved following treatment, though adults with FMPP are still slightly below average in height (5, 6). Long-term effects on fertility are still unknown, however one study did not show any differences in sperm count between patients taking anastrozole and controls (14). Patients seem to have preserved fertility in case reports (15). Until long-term data on adult height, fertility and bone health are available from a larger sample of patients, this combination therapy should be used judiciously. Endocrinologists should also keep in mind that the cost of therapy using bicalutamide and anastrozole is relatively more expensive than previous treatments (4).

Some studies have attempted to establish an association between phenotype and genotype (16, 17), which may alter treatment strategy due to variability in medication effectiveness. The traditional mutation in FMPP is Asp578Gly, resulting in an activation of LHCGR (2). However, other mutations have been known to cause FMPP (13). Approximately 55% of these “other” activating mutations occur at the 578 position, changing the aspartate residue a tyrosine, histidine, glycine, or glutamine (1).

To our knowledge, our patient has a novel mutation in the LHCGR gene, with a change from an A to a C, changing aspartate to alanine in the 578 position. Our patient has been responding well to therapy, likely because he has a mutation in the “typical” spot. But, this new mutation could explain some of the phenotypic differences in our patient as compared to the typical FMPP patient. Typically, FMPP presents at the age of 2-4 years. Our patient had initial symptoms much earlier than that at 6 months of age, which has only been documented in a handful of cases (13).

What remains unknown is what long-lasting effects remain from these increased hormone levels. It is known that testosterone has effects on the brain and on behavior, and increased levels can lead to aggressiveness, ADHD and developmental issues (3).

Though duration of the androgen exposure may be related to level of aggressiveness in children (18), and this aggressiveness tends to disappear with treatment (11), there are no studies examining the long-term effects.

Additionally, our patient had bilateral testicular microlithiasis. Typically found incidentally, testicular microliths occur with a prevalence of 2.4-5.6% in asymptomatic pediatric patients (19). Their cause is unknown, but it is thought to be a degenerative process in the seminiferous tubules leading to accumulation of cellular debris, and then accumulation of glycoproteins surrounding it, which then calcify (20, 21). It is noted that they do not typically affect Leydig cells, and maybe associated with Sertoli cell dysfunction (19). However, there is some evidence that microliths are associated with Leydig cell hyperplasia in rats (22). They are seen more frequently in children with Down syndrome and associated with testicular torsion, varicocele, retractile testes, cryptorchidism, inguinal hernias, and testicular neoplasms, though there is no evidence that they are premalignant (19, 20). The microliths in our patient may well be an incidental finding, however, testicular changes have been observed in FMPP in more than one case. Premature differentiation in all major testicular cell types, seminomas, and germ cell neoplasia in-situ (13, 15), and in particular, Leydig cell hyperplasia (2, 3, 13) have all been reported. Given the recent findings of microliths being associated with Leydig cell hyperplasia, and the known association between FMPP and Leydig cell hyperplasia, there may be a link between the two (2). Despite this, there has only been one other report of testicular microlithiasis (13).

Conclusions

FMPP is a rare disorder that is still being studied. No treatment guidelines have been established for this condition. Definitive evidence of effective treatment modalities has been weak, primarily because of the limited number of reported cases, small sample sizes, and short-term outcomes. However, this case study adds to the literature by demonstrating a novel mutation that responded well to a combination of bicalutimide and anastrozole.

Author contributions:

SG follows the patient. All authors were involved in writing the paper and had final approval of the submitted and published versions.

Ethics

Ethics Committee Approval: Not obtained/not applicable

Informed Consent: Yes, from patient’s mother

Authorship Contributions

Surgical and Medical Practices: Shilpa Gurnurkar

Concept: Shilpa Gurnurkar

Design: Not applicable

Data Collection or Processing: Shilpa Gurnurkar, Emily DiLillo, Mauri Carakushansky

Analysis or Interpretation: Not applicable

Literature Search: Shilpa Gurnurkar, Emily DiLillo, Mauri Carakushansky

Writing: Shilpa Gurnurkar, Emily DiLillo, Mauri Carakushansky

Conflict of Interest: No conflict of interest

Financial Disclosure: No financial disclosure

References

- (1) Qiao J, Han B. Diseases caused by mutations in lutenizing hormone/chorionic gonadotropin receptor. In: Tao YX, editor. Progress in molecular biology and translational science: G protein signaling pathways in health and disease. Cambridge: Academic Press, 2019: 69-89.
- (2) Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr. A constitutively activating mutation of the lutenizing hormone receptor in familial male precocious puberty. Nature 1993;365:652-4.
- (3) Narayan P. Genetic models for the study of lutenizing hormone receptor function. Front Endocrinol (Lausanne) 2015;6:152. doi: 10.3389/fendo.2015.00152.

- (4) Lenz AM, Shulman D, Eugster EA, Rahhal S, Fuqua JS, Pescovitz OH, Lewis KA. Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. *Pediatrics* 2010;126(3):e728-33. doi:10.1542/peds.2010-0596.
- (5) Lane LC, Flowers J, Johnstone H, Cheetham T. Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management. *J Pediatr Endocrinol Metab* 2018;31:551-60.
- (6) Leschek EW, Flor AC, Bryant JC, Jones JV, Barnes KM, Cutler GB Jr. Effect of antiandrogen, aromatase inhibitor, and gonadotropin-releasing hormone analog on adult height in familial male precocious puberty. *J Pediatr* 2017;190:229-35.
- (7) Mitre N, Lteif A. Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor. *J Pediatr Endocrinol Metab* 2009;22:1163-7.
- (8) Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. *J Pediatr* 2006;149:416-20.
- (9) Schoelwer M, Eugster EA. Treatment of peripheral precocious puberty. *Endocr Dev* 2016;29:230-9.
- (10) Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. *J Clin Endocrinol Metab* 1999;84:175-8.
- (11) Laue L, Kenigsbery D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB Jr. Treatment of familial male precocious puberty with spironolactone and testosterone. *N Engl J Med* 1989;320:496-502.
- (12) Kor Y. Central precocious puberty in a case of late-diagnosed familial testotoxicosis and long-term treatment monitoring. *Hormones (Athens)* 2018;17:275-8.
- (13) Özçabi B, Bucak FT, Ceylaner S, Özcan R, Büyükkınal C, Ercan O, et al. Testotoxicosis: Report of two cases, one with a novel mutation in LHCGR gene. *J Clin Res Pediatr Endocrinol* 2015;7:242-8.
- (14) Maura N, Bell J, Snow BG, Winslow KL. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. *Fertil Steril* 2005;84:239-42.
- (15) Juel Mortensen L, Blomberg Jensen M, Christiansen P, Rønholdt AM, Jørgensen A, Frederiksen H, et al. Germ cell neoplasia in situ and preserved fertility despite suppressed gonadotropins in a patient with testotoxicosis. *J Clin Endocrinol Metab* 2017;102:4411-6.
- (16) Müller J, Gondos B, Kosugi S, Mori T, Shenker A. Severe testotoxicosis phenotype associated with Asp578-->Tyr mutation of the lutrophin/choriogonadotrophin receptor gene. *J Med Genet*. 1998;35(4):340-341. doi:10.1136/jmg.35.4.340.
- (17) Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, Wu SM, Blomberg L, Cutler GB Jr. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. *Proc Natl Acad Sci USA* 1995;92:1906-1910.
- (18) Kulshreshtha B, Mehta M, Gupta N, Ammini AC. Behavioral aggressiveness in boys with sexual precocity. *Indian J Endocrinol Metab* 2012;16:395-9.
- (19) Goede J, Hack WW, van der Voort-Doedens LM, Sijstermans K, Pierik FH. Prevalence of testicular microlithiasis in asymptomatic males 0 to 19 years old. *J Urol* 2009;182:1516-20.
- (20) Ganem JP, Workman KR, Shaban SF. Testicular microlithiasis is associated with testicular pathology. *Urology* 1999;53:209-13.
- (21) Dutra RA, Perez-Bóscollo AC, Melo EC, Cruvinel JC. Clinical importance and prevalence of testicular microlithiasis in pediatric patients. *Acta Cir Bras* 2011;26:387-90.
- (22) Gougoudi E, Zachariou Z, Kogia E, Zavitsanakis A. Testicular microlithiasis and Leydig cell proliferation in Wistar rats underwent Fowler-Stephens procedure. *Pediatr Med Chir* 2012;34:192-7.

Figure 1. Patient's growth chart indicating height measurements with corresponding bone age readings before and after treatment initiation

